Femtobiomed, Inc.
KKRX:32761030.00
KRW
-5.00
(-14.29%)
ISIN
KR7327610002
Return %
Stock
S&P 500
1Y
-99.21
14.39
3Y
-99.60
81.42
5Y
-99.83
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Hyeon Lee
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Jul 10, 2019
- Website
- femtobiomed.com
- Similar Companies
- Business
- Femtobiomed, Inc. is a South Korea-based biotechnology company specializing in the development and commercialization of non-viral intracellular delivery platforms and automated bioprocessing systems for cell and gene therapy (CGT) manufacturing. The company operates through specialized biotechnology and life sciences equipment segments, offering a comprehensive product and service portfolio that includes: the CellShot platform, utilizing proprietary Partitioned Flow Electroporation (PFEP) technology to deliver genetic materials directly into target cells within standard culture media without cytotoxic mixing; the CellShot Badger series, including the cGMP-compliant CellShot Badger-700 and Badger-700D instruments engineered for scalable, high-throughput, and temperature-controlled electroporation of payloads such as mRNA, DNA, and CRISPR-Cas gene-editing complexes; the CellShot Turtle system, an automated sample processing unit designed for high-efficiency, small-scale research screening and contamination-free therapeutic workflow optimization; specialized bioprocessing consumables and reagents, including Proliva protective delivery buffers and Cryoliva specialized cryopreservation solutions; and tailored cell engineering services, process development consulting, and technical integration support for biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and academic research institutes. Its solutions primarily target developers in immuno-oncology, chimeric antigen receptor (CAR) cell therapeutics, regenerative medicine, and neoantigen cancer vaccines across South Korea, North America, and international markets. In recent operational and strategic developments, Femtobiomed secured a U.S. Food and Drug Administration (FDA) Drug Master File (DMF) registration (MF #30803) for its CellShot Badger platform, enabling clinical-stage biopharmaceutical clients to reference its hardware and validation data directly in regulatory filings. The company has also expanded its commercial product suite through the market introduction of the CellShot Turtle automation module and broadened its clinical collaborative ecosystem by entering into a strategic research partnership with Johns Hopkins University to advance personalized neoantigen cellular therapeutics, alongside pursuing global original equipment manufacturer (OEM) distribution channels. Founded in 2011, Femtobiomed, Inc. is headquartered in Seongnam-si, Gyeonggi-do, South Korea.